Monique Barbour, MD
Ophthalmology · Lake Worth Fl, FLNPI 1043398175
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $95,880 of the $151,232 with a category attached, or 63.4%. Sun Pharmaceutical Industries Inc. accounts for 63.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $64,678 and has fallen 64.4% since, to $23,041 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 588 payments — averaging $257.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$96K
- Oyster Point Pharma, Inc.$20K
- Thea Pharma Inc.$9K
- AbbVie$6K
- Bausch & Lomb Americas Inc.$5K
- Astellas Pharma US Inc$3K
- plus $12K from 29 others
Across 63 payments — averaging $2018.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$89K
- GSK$38K
What the payments were for
- Consulting fees$19,19513%
- Speaking & faculty fees$95,88063%
- Travel & lodging$15,46510%
- Food & beverage$20,54614%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$93,860
- TYRVAYA$18,321
- IYUZEH$6,183
- XIIDRA$4,864
- MIEBO$3,831
- Izervay$3,269
- DURYSTA$2,139
- CIRRUS HD-OCT$1,432
- IOLMaster 700$1,432
- VERACITY SURGICAL$1,432
- VisuMax$1,432
- RESTASIS MULTIDOSE$1,130
- TEPEZZA$812
- ACTHAR$628
- XEN GLAUCOMA TREATMENT SYSTEM$510
- LUMIGAN$488
- BROMSITE$393
- XELPROS$393
- RayOne EMV$369
- RayOne Spheric$369
How this compares
$151,232 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 236 | $226,977 |
| CequaCyclosporine | 235 | $168,984 |
| VabysmoFaricimab-Svoa | 30 | $86,202 |
| XiidraLifitegrast | 44 | $48,579 |
| TyrvayaVarenicline Tartrate | 70 | $46,897 |
| CombiganBrimonidine Tartrate/Timolol | 136 | $45,014 |
| EyleaAflibercept | 11 | $35,150 |
| XdemvyLotilaner | 18 | $34,379 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $19,267 |
| LumiganBimatoprost | 39 | $17,945 |
| Cyclosporine | 52 | $17,181 |
| MieboPerfluorohexyloctane/Pf | 16 | $15,860 |
| Alphagan PBrimonidine Tartrate | 45 | $14,091 |
| RhopressaNetarsudil Mesylate | 26 | $13,204 |
| IyuzehLatanoprost/Pf | 31 | $10,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $6,338 | $304,027456 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $96,426 | $168,984235 claims |
| Genentech USA, Inc.Vabysmo | $240 | $86,20230 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $4,611 | $64,43960 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $19,674 | $46,89770 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,862 | $34,37918 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $225 | $32,47150 claims |
| Thea Pharma Inc.Iyuzeh | $8,671 | $10,15331 claims |
| AlconSimbrinza | $985 | $4,62120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Lake Worth Fl
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.